Episode Details

This newsletter from Indy Sawhney provides a strategic framework for calculating the Return on Investment (ROI) of agentic AI within the pharmaceutical industry. It emphasizes that traditional financial models often fail because they ignore the high program costs of regulated deployments and rely too heavily on minor labor savings. Instead, the text argues that the primary financial value of AI stems from timeline compression, which allows drugs to reach the market faster. To secure funding, leaders are encouraged to collaborate with CFOs and technical stakeholders to validate these assumptions with real production data. Ultimately, the source serves as a practical playbook for navigating the complex financial and regulatory realities of large-scale AI adoption.